TVTX (Travere Therapeutics) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TVTX Travere Therapeutics Inc TVTX
61 GF Score
Price $65.71
GF Value $36.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Travere Therapeutics Defensive Interval Ratio?

TVTX
61GF Score
Travere Therapeutics Inc TVTX
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Travere Therapeutics (TVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued. The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75. GuruFocus considers Travere Therapeutics to be Significantly Overvalued.

Key valuation signals for TVTX:

  • Defensive Interval Ratio:
  • GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Travere Therapeutics Business Description

Address 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score

Get the complete analysis for TVTX

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.71
Price
$36.75
GF Value